Open AccessA Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
Author(s) -
Alexandra K. Suchowerska,
Geurt Stokman,
James T. Palmer,
Phillip A. Coghlan,
Elsbet J. Pieterman,
Nanda Keijzer,
Gilles Lambert,
Kévin Chemello,
Ali K. Jaafar,
Jasneet Parmar,
Liping Yan,
Yingtao Tong,
Lin Mu,
P. Hans,
J. Bonnar,
Benny J. Evison
Publication year - 2022
Publication title -
journal of lipid research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 192
eISSN - 1539-7262
pISSN - 0022-2275
DOI - 10.1016/j.jlr.2022.100293
Subject(s) - pcsk9 , ldl receptor , kexin , chemistry , cholesterol , proprotein convertase , familial hypercholesterolemia , apolipoprotein b , in vivo , endocrinology , pharmacology , medicine , lipoprotein , biochemistry , biology , microbiology and biotechnology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom